Bionomics Ltd. - ADR
BNOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.61K
Close$
$0.79
211.5% upside
Current Fair Value
211.5% upsideUndervalued by 211.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7,609.00 |
|---|---|
| Enterprise Value | $-19,823,577.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-550.8 |
| Beta | -0.07 |
| Outstanding Shares | 30,062 |
Return
| Return on Equity | -54.68% |
|---|---|
| Return on Assets | -46.86% |
| Return on Invested Capital | -39.67% |
Valuation & Multiples
| P/E Ratio | -0.47 |
|---|---|
| PEG | 0.48 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -12.67 |
| Enterprise Value to EBIT | 1.34 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bionomics Ltd.
1 employees
CEO: Spyridon Papapetropoulos Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals l...